Cerevel’s path to NASDAQ via a SPAC is likely to presage similar deals for other life sciences companies. Biotechs and investors have increasingly made use this year of special purpose acquisition companies, which are blank-check...

HBM Partners completed a €90 million ($117.6 million) first close of its HBM BioCapital II fund that will invest in revenue-generating life sciences companies. The firm expects a final close of €120-€150 million ($156.8-$196 million)...

HBM Partners raised EUR 90 million ($117.6 million) in the first close of its HBM BioCapital II fund, which will invest in revenue-generating life sciences companies. HBM expects a final close of EUR 120-EUR 150...

HBM Partners ' track record of eight exits from 15 investments in its first fund clearly gained the attention of LPs, as the firm has completed a €90 million ($117.6 million) first close on a...

HBIO's BTX Harvard Apparatus subsidiary granted Nanoentek's Digital Bio subsidiary exclusive distribution rights to electroporation products for gene delivery in certain Asian countries. Also, Digital Bio granted BTX Harvard exclusive distribution rights to Microporator, a...